A Randomized Open-Label Parallel-Group Multi-Center Study of Adding Edoxaban or Clopidogrel to Aspirin to Maintain Patency in Subjects with Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention- Edoxaban in Peripheral Arterial Disease (EPAD)
ID Number 13-0514Principal Investigator(s)
Ageliki G Vouyouka
Department(s) or Division(s)
Peripheral Arterial Disease (PAD) is primarily caused by atherosclerosis, or hardening of the arteries. Its diagnosis frequently indicates high cardiovascular risk, reduced productivity, and reduced quality of life. Clearing an open path for blood flow by endovascular interventions is the preferred treatment. However, the incidence of re-stenosis is high, resulting in the frequent need for multiple re-interventions. There is evidence to support the general use of low-dose aspirin in patients with PAD, but no clinical trial evidence regarding the efficacy of current antithrombotic drugs for the prevention of re-occlusion of peripheral arteries. This study investigates the use of the anticoagulant Edoxaban for use in PAD patients after femoropopliteal endovascular interventions for the maintenance of patency and prevention of re-intervention.
Recruiting Patients: Yes